摘要
目的:探讨分化型甲状腺癌(DTC)术后碘-131(^(131)I)治疗患者血清甲状腺球蛋白(Tg)、巨噬细胞炎性蛋白-1α(MIP-1α)、谷胱甘肽过氧化物酶3(GPX3)与预后的关系。方法:接受手术联合^(131)I治疗的DTC患者180例作为DTC组,根据^(131)I治疗后2年是否复发/转移将DTC患者分为预后不良组和预后良好组。检测血清Tg、MIP-1α、GPX3水平。通过Logistic回归分析DTC术后^(131)I治疗患者预后的影响因素。结果:与预后良好组比较,预后不良组血清Tg、MIP-1α水平升高,GPX3水平降低(P<0.05)。DTC术后^(131)I治疗患者预后不良的独立危险因素为TNM分期III-IV期和Tg、MIP-1α升高,而GPX3升高为独立保护因素(P<0.05)。结论:DTC术后^(131)I治疗患者血清Tg、MIP-1α水平升高和GPX3水平降低与预后不良密切相关。
Objective:To investigate the relationship between serum thyroglobulin(Tg),macrophage inflammatory protein-1α(MIP-1α),glutathione peroxidase 3(GPX3)and the prognosis in patients treated with iodine-131(^(131)I)after differentiated thyroid cancer(DTC)surgery.Methods:180 DTC patients who received surgery combined with ^(131)I treatment were selected as the DTC group,and patients were divided into poor prognosis group and good prognosis group according to whether they had recurrence/metastasis at 2 years after ^(131)I treatment.Detected serum Tg,MIP-1αand GPX3 levels.The factors affecting the prognosis of patients treated with ^(131)I after DTC surgery were analyzed by Logistic regression.Results:Compared with the good prognosis group,serum Tg and MIP-1αlevels were increased and GPX3 levels were decreased in the poor prognosis group(P<0.05).The independent risk factors for poor prognosis in patients treated with ^(131)I after DTC surgery were TNM stage III-IV and elevated Tg,and MIP-1α,and elevated GPX3 was an independent protective factor(P<0.05).Conclusion:Elevated serum Tg,MIP-1αlevels and reduced GPX3 levels are closely associated with poor prognosis in patients treated with ^(131)I after DTC surgery.
作者
顾胤烨
陈建栋
孔宪诚
陈晨
詹有芳
周伟
邬晓丽
石磊
GU Yin-ye;CHEN Jian-dong;KONG Xian-cheng;CHEN Chen;ZHAN You-fang;ZHOU Wei;WU Xiao-li;SHI Lei(Department of Clinical Laboratory,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,200120,China;Department of General Surgery,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,200120,China)
出处
《现代生物医学进展》
CAS
2024年第19期3641-3644,共4页
Progress in Modern Biomedicine
基金
上海市教育委员会自然科学类科研基金资助项目(18TS080)
上海中医药大学预算内项目(2022YJ-20)。